Advanced Search
Janssen Pharmaceutica

Janssen Pharmaceutica

A pharmaceutical company that is in partnership with Johnson & Johnson. It is based in Beerse, Belgium and was founded in 1953.


Janssen Pharmaceutica develops treatment for patients worldwide in the following therapeutic areas of healthcare: Cardiovascular & Metabolism , Immunology , Infectious Diseases & Vaccines , Neuroscience , Oncology and Pulmonary Hypertension. Janssen partners with academic researchers, governments, patient groups, healthcare professionals, and others in their research. Janssen's activities range from initial basic research and production to commercial and support services and sale of medicines. Janssen Pharmaceutica operates as a subsidiary of Johnson & Johnson.


Janssen Pharmaceutica has been working with its parent company to create a medicine to aid with the COVID-19 pandemic. It is using non-replicating viral vector as well as Ad26 (alone or with modified vaccina Ankara boost) technology to conduct studies on how the vaccine can be used in the pandemic.


May 19, 2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announces new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study.




Ai Hua Ong

Company Group Chairman, Asia Pacific

Elizabeth Blackwood

Vice President and Chief Quality Officer, Pharmaceuticals

Elizabeth Forminard

General Counsel, Pharmaceuticals

Jane Griffiths, Ph.D.

Global Head, Actelion

Jeff Steinhorn

Chief Information Officer, Pharmaceuticals, Head of Enterprise Functions, Johnson & Johnson Technology

Jennifer Taubert

Executive Vice President Worldwide Chairman, Pharmaceuticals Johnson & Johnson

Joaquin Duato

Vice Chairman of the Executive Committee Johnson & Johnson

Kris Sterkens

Company Group Chairman, Europe, Middle East, and Africa

Kristen Mulholland

Head of Human Resources, Global, Pharmaceuticals Group and External Innovation

Linda Fedow

Global Lead, Pharmaceutical Communication & Public Affairs

Mathai Mammen, M.D., Ph.D.

Global Head, Research and Development

Patrick Verheyen

Global Head, Janssen Business Development

Paul Stoffels M.D.

Vice Chairman of the Executive Committee, Chief Scientific Officer Johnson & Johnson

Pete Batesko

Vice President, Group Finance, Pharmaceuticals

Remo Colarusso

Vice President, Janssen Supply Chain

Richard Tillyer, Ph.D.

Global Head, Discovery, Product Development & Supply, Jannsen Research & Development

Scott White

Company Group Chairman, North America Pharmaceuticals, Johnson & Johnson

Stef Heylen, M.D.

Chief Operating Officer, Development, Janssen Research & Development

Tom Heyman

Chief Executive Officer

Vanessa Broadhurst

Chief Operating Officer, Development

Further reading


How one pharmaceutical company is reinventing the clinical trial - STAT

Andreas Koester


September 21, 2018

Janssen Pharmaceutical Companies Expands R&D at San Francisco, California Campus - Area Development

Area Development News Desk


January 13, 2020

Documentaries, videos and podcasts


2019 Dr. Paul Janssen Award Celebration




May 21, 2021
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE® - read this article along with other careers information, tips and advice on BioSpace
Halozyme Therapeutics, Inc.
May 21, 2021
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Pharmaceutica N.V. (Janssen) received two positive opinions from the...
April 8, 2021
The Indian Express
Over the last year, India has been building capabilities to manufacture large quantities of vaccines like Sputnik V, Covovax and the Janssen vaccine.
Insilico Medicine Hong Kong Limited
November 10, 2020
/PRNewswire/ -- Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of...
January 6, 2020
Nominations are now being accepted for the 2020 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates dedicated researchers and champions of science whose basic or clinical discoveries have made, or have the potential to make, significant contributions toward improving human health. Nominations will be accepted until February 29, 2020, at for consideration by an independent selection committee of world-renowned scientists. The winning...
July 16, 2019
Johnson & Johnson today announced that it is extending through 2025 global product donations of an intestinal worms treatment made by its Janssen Pharmaceutical Companies. The new five-year expanded commitment will ensure that one billion doses of VERMOX® CHEWABLE (mebendazole chewable 500mg tablets) are provided in the 2021-2025 period to high-burden countries via donations to the World Health Organization (WHO), which manages and coordinates country requests for this valuable medicine. A...


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.